TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 136nMAssay Description:Displacement of H3K14Ac from BAZ2B (unknown origin) preincubated for 30 mins with non-biotinylated peptide followed by addition of biotinylated pepti...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 160nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 316nMAssay Description:Inhibition of BAZ2A (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 550nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 580nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 720nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 880nMAssay Description:Binding affinity to human partial length BAZ2A expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 880nMAssay Description:Binding affinity to human partial length BAZ2A expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 890nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.10E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.20E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.20E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.40E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.50E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.70E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.80E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.80E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.30E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 4.00E+3nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 4.10E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 4.10E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 6.31E+3nMAssay Description:Inhibition of BAZ2A (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 7.20E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 8.60E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.06E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.09E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.10E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.10E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.14E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.18E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.25E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.26E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.29E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.31E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.40E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.41E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.20E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.51E+4nMAssay Description:Inhibition of BAZ2A (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.51E+4nMAssay Description:Inhibition of BAZ2A (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.92E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.13E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: <3.16E+4nMAssay Description:Inhibition of human BAZ2A by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.32E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.32E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair